Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23933526 | 1.00 | JAK1 (0.41) | JAK1AURKAEPHX2NOTUMPIK3CD | |
| SCHEMBL23933530 | 1.00 | JAK1 (0.41) | JAK1AURKAEPHX2NOTUMPIK3CD | |
| SCHEMBL23499427 | 0.90 | JAK1 (0.42) | JAK1AURKAPIK3CDPIK3CAPIK3CB | |
| SCHEMBL23499429 | 0.90 | JAK1 (0.42) | JAK1AURKAPIK3CDPIK3CAPIK3CB | |
| SCHEMBL23499425 | 0.90 | JAK1 (0.42) | JAK1AURKAPIK3CDPIK3CAPIK3CB | |
| SCHEMBL23499440 | 0.84 | JAK1 (0.38) | JAK1AURKAEPHX2NOTUMPIK3CD | |
| SCHEMBL31119103 | 0.84 | ATXN2 (0.45) | JAK1AURKAEPHX2PIK3CDPIK3CA | |
| SCHEMBL24575288 | 0.84 | ATXN2 (0.45) | JAK1AURKAEPHX2PIK3CDPIK3CA | |
| SCHEMBL23933595 | 0.83 | GRIN2B (0.39) | JAK1AURKAJAK2SSTR4 | |
| SCHEMBL23933599 | 0.83 | GRIN2B (0.39) | JAK1AURKAJAK2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| EP-4139303-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021216951-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM3, CHRM2, CHRM4 | JAK1 3042/4885AURKA 3296/4885EPHX2 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.